Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
August 11, 2022 07:00 ET
|
Optinose, Inc.
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis...
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
August 08, 2022 16:20 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
July 13, 2022 07:00 ET
|
Optinose, Inc.
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark...
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
July 08, 2022 07:00 ET
|
Optinose, Inc.
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
June 13, 2022 07:00 ET
|
Optinose, Inc.
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times...
Optinose Reports First Quarter 2022 Financial Results and Operational Updates
May 12, 2022 07:00 ET
|
Optinose, Inc.
Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021 Company expects top-line results from the second of two clinical trials evaluating...
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
May 05, 2022 17:00 ET
|
Optinose, Inc.
Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients...
Optinose to Present at the Needham Virtual Healthcare Conference
April 08, 2022 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., April 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
March 08, 2022 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
March 07, 2022 07:00 ET
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...